Adoption of additional technology solutions demonstrates commitment to patients with cancer and other serious diseases.

Medidata, a Dassault Systemes company and the global leader in creating end-to-end solutions to support the entire clinical development process, today announced its expanded partnership with Karyopharm Therapeutics (NASDAQ: KPTI). In 2014, Karyopharm selected one Medidata technology solution for a single study. Today, the company is leveraging 10 solutions in Medidata Rave Clinical Cloud in more than 15 clinical studies focused on hematologic malignancies and solid tumors.

'Medidata is pleased to play a key role in supporting Karyopharm's mission of bringing novel therapies to market, providing hope for patients,' said Glen de Vries, co-founder and co-CEO, Medidata. 'This agreement is a clear demonstration of our shared mission to advance analytics and technology to make a difference in health care.'

With Medidata solutions, Karyopharm is able to:

Centralize operations, eliminate manual data entry, and operate with a clear view of all cross-application data in one place

Simplify and customize reporting within or across studies and leverage over 30 standard reports

Reduce complexity by standardizing and improving data quality with powerful artificial intelligence and machine learning algorithms that automatically manage the complexity of clinical data

'Medidata continues to be an important strategic partner for Karyopharm by providing a cutting-edge technological infrastructure that helps us reach our clinical trial goals,' said Kristan Gallitano, senior vice president, Development Operations at Karyopharm. 'Medidata provides us the flexible, scalable technology and support we need to meet the evolving challenges of drug development.'

Medidata is a wholly owned subsidiary of Dassault Systemes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate evidence and insights to help pharmaceutical, biotech, medical device, and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systemes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.

Medidata, Rave, and myMedidata are registered trademarks of Medidata Solutions, Inc., a wholly-owned subsidiary of Dassault Systemes.

About Dassault Systemes

Dassault Systemes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating 'virtual experience twins' of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production.

Dassault Systemes' 20,000 employees are bringing value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit https://www.3ds.com

(C) 2021 Electronic News Publishing, source ENP Newswire